 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq: AVEO today announced the presentation of results from the Phase 1b portion of the Phase 1b2 DEDUCTIVE clinical trial of tivozanib FOTIVDA, AVEOs vascular endothelial growth factor receptor VEGFR tyrosine kinase inhibitor TKI drug candidate, in combination with IMFINZI durvalumab, AstraZenecas LSESTONasdaq: AZN human monoclonal antibody directed against programmed death-ligand 1 PD-L1, in patients with advanced or metastatic hep 